Abstract: The upregulation of heme oxygenase-1 (HO-1) is one of the most important mechanisms of cell adaptation to stress. Indeed, the redox sensitive transcription factor Nrf2 is the pivotal regulator of HO-1 induction. Through the antioxidant, antiapoptotic, and antiinflammatory properties of its metabolic products, HO-1 plays a key role in healthy cells in maintaining redox homeostasis and in preventing carcinogenesis. Nevertheless, several lines of evidence have highlighted the role of HO-1 in cancer progression and its expression correlates with tumor growth, aggressiveness, metastatic and angiogenetic potential, resistance to therapy, tumor escape, and poor prognosis, even though a tumor- and tissue-specific activity has been observed. In this review, we summarize the current literature regarding the pro-tumorigenic role of HO-1 dependent tumor progression as a promising target in anticancer strategy.

Keywords: HO-1; Nrf2; cancer progression; tumor microenvironment; immune-escape; oxidative stress; NK; melanoma; NSCLC; prostate cancer

1. Introduction

Heme oxygenase-1 (HO-1) is one of the three isoforms of heme oxygenase, the first rate-limiting enzyme in the degradation of heme to free iron, carbon monoxide (CO), and biliverdin [1,2]. HO-1 is a 32-kDa inducible protein identified in 1990 as a stress protein involved in antioxidant and anti-inflammatory responses [3]. HO-1 is present at low levels in most mammalian tissues and is highly upregulated by a number of oxidative stimuli such as its substrate heme, heavy metals, UV irradiation, ROS, modified lipids, growth factor, and inflammatory cytokines [3–5]. HO-1 is mainly localized in microsomes [6], but it has also been demonstrated to be present in caveolae [7], mitochondria [8], and nuclei [9].

The cytoprotective activity of HO-1 is exerted by its metabolites [2,10] (Figure 1). Indeed, the release of free iron favors the synthesis of the heavy chain of ferritin, an iron chelating protein, and the activation of the membrane transporter Fe-ATPase, which permits cytosolic iron efflux, decreasing the intracellular Fe\(^{2+}\) content preventing the generation of ROS through the Fenton reaction [11,12]. Furthermore, carbon monoxide exerts antiapoptotic and anti-inflammatory effects through the induction of soluble guanylyl cyclase (sGC), elevation of cGMP, and modulation of mitogen-activated protein kinase pathway (MAPK) [2,10,13]. As a consequence, HO-1–derived CO stimulates blood vessel formation [14], induces VEGF synthesis [15], and favors the proliferation of
endothelial cells [16] crucially involved in wound healing [17]. In addition, bilirubin (BR) derived from biliverdin (BV) by biliverdin reductase (BVR), exerts strong antioxidant [18], antiapoptotic [10], and anti-inflammatory activity [19]. In fact, bilirubin is able to scavenge hydroxyl radical, singlet oxygen, and superoxide anions [20] and prevents protein and lipid peroxidation [21,22]. Moreover, bilirubin exerts anti-inflammatory effects decreasing P- and E-selectin expression, preventing leucocyte rolling and inhibiting the complement cascade [6]. Recent studies have also demonstrated that HO-1 plays an important role in immune regulation promoting immune tolerance [23].

Thus, the biological properties of HO-1 have been mainly ascribed to its enzymatic activity. However, HO-1 can also act independently of its enzymatic function. Indeed, it has been shown that HO-1 can move into the nucleus and regulate gene transcription, specifically favoring cancer tumor growth [9,24].

HO-1 is highly induced in oxidative stress conditions. Its synthesis is regulated mainly at a transcriptional level [13,25]. In the promoter region of HO-1, in fact, several binding sites are present for different transcription factors that can be activated in oxidative stress conditions like AP-1, HIF-1, NF-kB, and Nrf2 [26]. Among these, Nrf2 is considered a key regulator of HO-1 transcription [13].

The nuclear factor erythroid 2 p45-related factor 2 (Nrf2) plays a pivotal role in maintaining cellular redox homeostasis. It belongs to the Cap ‘n’ Collar (Cnc)-bZIP (basic leucine zipper) family of transcription factors together with Nrf1 and Nrf3 [27] as well as the transcriptional repressors Bach1 and Bach2 [28]. Nrf2 protein has a seven-domain structure which accounts for its binding to repressors and to DNA [29–31]. The binding with the E3 ubiquitin ligase Kelch ECH-associating protein 1 (Keap1) provides its constant proteasomal degradation in resting condition. When Keap1 is modified by oxidative or electrophilic stressors, Nrf2 becomes free to move into the nucleus, where it dimerizes with Maf proteins and binds antioxidant/electrophile-response elements (ARE/EpRE sequences) [31–33] leading to the transcription of target genes. Among these, a plethora of antioxidant and detoxifying enzymes involved in cell resistance to stress have been identified as well as regulators of cell proliferation and differentiation [27,34–37].

Furthermore, other mechanisms can induce Nrf2 activation. Due to its interaction with sequestosome-1 protein (p62/SQSTM1), Keap1 is sequestered in autophagosomes. As a consequence, Nrf2 ubiquitination decreases leading to its prolonged activation in response to oxidative stress [38,39].

![Figure 1. Heme degradation pathway. Heme oxygenase-1 (HO-1) catalyzes the degradation of heme to equimolar amounts of carbon monoxide (CO), biliverdin, and ferrous iron in presence of molecular oxygen (O2) and nicotinamide adenine dinucleotide phosphate (NADPH). Biliverdin is subsequently converted to bilirubin by biliverdin reductase (BVR).](image-url)
It has been also demonstrated that, in a Keap1-independent manner, β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP) and Glycogen Synthase Kinase 3β (GSK-3β) can induce the ubiquitination and proteasomal degradation of Nrf2 [40].

Notably, in cancer cells, further mechanisms of amplification of Nrf2 signaling have been described [30]. Genetic modifications of Nrf2/Keap1, mainly gain-of-function mutations of Nrf2 and loss-of-function mutations of Keap1, lead to a constitutive activation of Nrf2 [41–44]. Moreover, epigenetic alterations in Keap1, such as Keap1/Cul3 hypermethylation, are responsible for the accumulation and aberrant activation of Nrf2 in lung [45], prostate [46], head and neck [47], colorectal [48], and ovarian cancer [49]. In addition, the Nrf2-Keap1 binding can be modified by the interaction with other proteins which increase Nrf2 stabilization [50]. For instance, p21 [51–53] as well as DJ-1 are able to bind Keap1, allowing Nrf2 to translocate into the nucleus [54]. Indeed, DJ-1 in cancer is often upregulated and increases the expression of detoxification enzymes providing a survival advantage [55–57].

It is important to note that the binding of Nrf2 to ARE sequences is highly complex and Bach1 represents another regulator of the transcription of Nrf2 target genes and of HO-1 in particular [58]. In fact, Bach1 is a heme-binding protein which, in unstressed conditions, dimerizes with Maf proteins and binds to the ARE/EpRE sequences, acting as transcriptional repressor of ARE-dependent genes. Under oxidative conditions or when the concentration of heme groups increases, a conformational change of Bach1 favors its displacement from ARE sequences and its degradation to proteasome, allowing Nrf2 to bind [58,59].

Notably, HO-1 activity is also regulated by specific compartmentalization of the enzyme. In fact, it has been identified as being active at a mitochondrial level in lung epithelial cells exposed to cigarette smoke, LPS, or hemin [60], while its localization at the plasma membrane prevents its catalytic activity. Indeed, in rat pulmonary artery endothelial cells it has been demonstrated that HO-1 activity is negatively modulated by Caveolin-1 (Cav-1) [7]. The five amino acid sequence in Cav-1 responsible for the binding to HO-1 has been identified [61] and the role of Cav-1 in the modulation of HO-1 activity has been recently proved by using a Caveolin-1 scaffolding domain (CSD) peptide able to decrease the compartmentalization of HO-1, increasing its activity in alveolar macrophages and in mice [62].

Therefore, in physiological conditions, the activation of Nrf2/HO-1 axis is involved in the maintenance of cellular homeostasis and plays a central role in adaptive response to cellular stress, representing a crucial point in cytoprotection, cell survival, and in the prevention of carcinogenesis [63–65]. By contrast, in cancer cells, a prolonged activation of Nrf2 and HO-1 is ambiguous and deleterious [30,31,66].

In this review, we focus our attention on HO-1 upregulation in cancer progression, analyzing its involvement in tumor growth, resistance to therapies, and in the gain of metastatic features. Moreover, a growing body of evidence demonstrates the involvement of HO-1 in the generation of a favorable microenvironment, promoting angiogenesis and immune-escape in many types of cancers including melanoma, brain tumors, NSCL, prostate cancer, and chronic myeloid leukemia [66–70] and this aspect will be also described.

2. HO-1 in Cancer Growth and Resistance to Therapy

HO-1 expression correlates with cancer growth and resistance to therapy as shown in different types of tumors such as human renal cell carcinoma [71], prostate and pancreatic cancers [10,72], lymphosarcoma [73], melanoma, and hepatoma [74]. Moreover, anticancer treatments such as chemo-, radio-, and photodynamic therapy further increase HO-1 expression [75] and it has been demonstrated that pharmacological inhibitors of HO-1 are able to sensitize cancers to therapies [74,76].

Several studies highlighted that cancer cells with high levels of HO-1 are less sensitive to the treatment with etoposide, doxorubicin, or cisplatin [77–80]. In fact, HO-1 overexpression protects from antitumor activity of cisplatin both Hep-2 laryngeal squamous cells and HepG-2 hepatoma cells as
well as MNK-4 gastric cancer cells and A549 lung cancer cells [80,81]. HO-1 inhibition or silencing enhances cytotoxicity [79,82] downregulating MMP-9 and VEGF levels and favoring apoptosis [80,81].

Moreover, HO-1 upregulation contributes to chemoresistance to doxorubicin or gemcitabine in urothelial cancers and in cholangiocarcinoma cell lines and its inhibition or silencing is able to increase ROS production and cytotoxicity and inhibit tumor growth in vivo [83–85]. In addition, siRNA HO-1 leads to the inhibition of neoplastic growth in human pancreatic cancer resistant to gemcitabine [86]. Interestingly, it has been shown that the autophagy pathway induced by the activation of Src/STAT3/HO-1 protects several subtypes of breast cancer cells from doxorubicin-induced cytotoxicity [78]. HO-1 is also overexpressed in melanoma cell lines after treatment with proteasome inhibitor bortezomib and with arsenic trioxide [87,88] and, in glioma cells, the resistance to arsenic trioxide is reverted by HO-1 inhibition obtained using Zinc II Protoporphyrin IX (ZnPPIX), leading to an enhanced apoptosis [89]. Furthermore, we have demonstrated that Nrf2-dependent HO-1 induction prevents neuroblastoma cell death after GSH depletion or bortezomib treatment and HO-1 inhibition or silencing restore cell sensitivity [77,90,91].

As far as the radio- and photodynamic-therapy (PDT) is concerned, the overexpression of HO-1 is involved in human lung adenocarcinoma and in urothelial cancer resistance to irradiation treatment and its inhibition induced by ZnPPIX or SnPPIX enhances radiosensitivity [83,92,93]. In addition, it has been demonstrated that HO-1 silencing sensitizes human urothelial as well as HeLa cervical cancer cells to 5-aminolevulinic acid-based photodynamic therapy [75,94] and that HO-1 siRNA or inhibition increase the PDT cytotoxicity in colon adenocarcinoma C-26 and human ovarian carcinoma MDAH2774 cells [95]. Also in melanoma cells, HO-1 inhibition increases the responsiveness to PDT therapy, leading to apoptosis [96].

HO-1 is involved in chemoresistance in solid tumors, but it seems, although not yet fully clarified, to play a role in hematopoietic malignancies as well. The drug-resistant acute myeloid leukemia (AML) cell line HL-60R is significantly less sensitive to cytarabine and daunorubicin than HL-60 cells and this correlates to HO-1 overexpression. Indeed, HO-1 downregulation significantly enhanced the sensitivity of HL-60R to chemotherapy [97]. Moreover, in the majority of AML patients, especially in those with acute monocytic leukemia and leukocytosis, HO-1 is aberrantly overexpressed. In this context, it has been demonstrated that in a mouse xenograft model of AML, HO-1 silencing extends the survival rate [98]. Furthermore, HO-1 protects AML cells from the apoptosis induced by proteasome inhibitor, bortezomib [99], or to front-line chemotherapeutic agents such as cytarabine and daunorubicin and HO-1 downregulation favors apoptosis [100]. The same results are observed in chronic myeloid leukemia resistant to imatinib by induction of autophagy [101,102]. Furthermore, in multiple myeloma the high expression of HO-1 stimulates the autocrine production of IL-6, one of the most important survival factors, and increases drug resistance and disease [103].

However, in some types of tumor, the role of HO-1 is controversial. Recently, it has been demonstrated that stable HO-1 overexpression retards hepatocellular carcinoma (HCC) progression, downregulating several onco-microRNA among which the most stably downregulated are miR-30d and miR-107 [104]. Moreover, in lung mucoepidermoid carcinoma, a rare subtype of non-small-cell lung cancer, HO-1 inhibits tumor growth by downregulating the oncogenic miR-378 and matrix metalloproteinases and this is confirmed in a murine xenograft model [105]. This different action of HO-1 overexpression in tumor is also related to invasiveness and metastatic potential, as described in paragraph 3.

3. HO-1 in Invasiveness, Angiogenesis, and Metastatic Potential

The gain of a metastatic phenotype is a key step in cancer progression and involves the acquisition of even more aggressive features that increase cell ability to move, overrun surrounding tissue, and favor the growth of new blood vessels in order to increase tumor mass and reach the bloodstream. Different findings prove the involvement of HO-1 in all these aspects of cancer progression.
HO-1 overexpression increases viability, proliferation, and angiogenic potential of melanoma cells favoring metastasis formation and decreasing tumor-bearing mouse survival [106]. Similarly, the high expression of HO-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients [107].

Moreover, HO-1 overexpression positively correlates to the thymidine phosphorylase (TP), a proangiogenic enzyme, overexpressed in different human tumors such as NSCLC, breast, and colorectal cancers [108,109] and contributes to higher microvessel density, metastasis, more advanced tumor stage, and poor prognosis [109]. HO-1 upregulation is also involved in osteoponin-induced glioma cell invasion and migration [110] and in breast cancer proliferation [111]. Moreover, it has been shown that brain-derived neurotrophic factor (BDNF), a potent neurotrophic factor involved in cancer cell metastasis and migration, increases the migration of colon cancer cells by regulating VEGF/HO-1 pathway [112].

In NSCLC, the invasive and migratory abilities induced by the exposure to high concentrations of glucose [113] significantly increase after HO-1 overexpression and decrease after HO-1 silencing, being strictly correlated with the expression level of metastasis-associated proteins EGFR, CD147, and MMP-9 [70]. Moreover, in the same kind of tumor cells, resveratrol inhibits metastasis formation, downregulating the expression of HO-1 and the level of matrix metalloproteinases [114].

It is noteworthy that HO-1 upregulation has been associated with tumor cell protection against anoikis, a specialized type of apoptosis which follows matrix detachments, contributing to metastatic properties of human fibrosarcoma cells [115].

Furthermore, the epithelial-to-mesenchymal transition (EMT) plays a key role in metastatic process [116,117]. It has been shown that in colon cancer cells the glucose-regulated protein 78 (GRP78) favors migration ability and invasiveness through the induction of vimentin expression, the reduction of E-cadherin level, and the activation of Nrf2/HO-1 signal pathway [118]. Moreover, in ovarian cancer cells, it has been demonstrated that the inhibition of autophagy promotes EMT through the increase in intracellular ROS and in the expression of HO-1 and that HO-1 inhibition treatment impairs the migration and invasion by reversing EMT [119].

Tumor invasiveness and metastasis are strictly related to the stimulation of angiogenesis. The role of HO-1 in angiogenesis is well documented both in vitro and in vivo [6,14,67,120–122]. HO-1 derived CO stimulates blood vessel formation [14] and induces VEGF [123] and stromal-cell-derived factor 1 (SDF-1) leading to angiogenesis [124]. Moreover, HO-1 overexpression promotes angiogenesis in urothelial carcinoma cells [121] and in human pancreatic cancer [125]. In colorectal cancer cells, HO-1 inhibition suppresses the expression of HIF-1α and VEGF and decreases the degree of angiogenesis in a mouse xenograft model [126]. In tumor-bearing mice, the use of ZnPPIX to inhibit HO-1 prevents peritoneal metastasis of gastric cancer by reducing angiogenesis [127]. In addition, as recently reported by Lin and coworkers, HO-1 expression in the tumor niche promotes lung metastasis by controlling VEGF and IL-10 production [122].

As previously described in paragraph 2, the role of HO-1 in tumor biology is controversial and specifically context-dependent. In particular, in some experimental models, the increased HO-1 expression is associated with the inhibition of angiogenesis, and the slowing of tumor growth. In fact, the upregulation of HO-1 in prostate cancer PC3 cells is associated with a decrease in cell proliferation and invasiveness [128] due to HO-1 dependent downregulation of the proangiogenic mediators VEGF and MMP-9 [129,130]. It has been also demonstrated that in lung mucopidermoid carcinoma (MEC) the Nrf2-dependent HO-1 activation is associated with a tumor-suppressive phenotype characterized by a strong downregulation of MMP-9 and MMP-13 and the attenuation of the metastatic potential [105]. In addition, carbon monoxide exposure inhibits tumor proliferation and microvascular density in xenotransplanted tumors [131] and human pancreatic cancer cells treated with carbon monoxide-releasing molecules show a significant inhibition of cell proliferation [131]. Finally, Skrzypek and coworkers identified a particular subtype of non-small-cell lung carcinoma (NSCLC) where HO-1 acts as a tumor suppressor, inhibiting cancer cell proliferation, migration, angiogenesis,
and tumor growth. Indeed, they demonstrated that the stable overexpression of HO-1 upregulates tumor-suppressive microRNA and downregulates the expression of onco- and angio-microRNA, such as miR-378 [132].

4. HO-1 in Tumor Immune-Escape

Tumor microenvironment consists of infiltrating immune cells, endothelial cells, extracellular matrix, and signaling molecules. Growth, invasiveness, and metastatic ability of tumors are mediated by cell interactions in this microenvironment [133,134]. Malignant cells have developed different mechanisms to escape from the immune system [135,136]. Many types of leukocytes such as B and T lymphocytes, neutrophils, macrophages, dendritic (DC), and natural killer (NK) cells can infiltrate tumors [137]. Even though tumor-specific cytotoxic T lymphocytes (TILs) and NK can eliminate tumor cells, there is increasing evidence that, in solid tumors and hematological malignancies, the high number of T regulatory (T$_{\text{reg}}$), a specialized sub-population of T cells, acts to suppress the immune response [138–141].

Numerous reports have shown that the degradation pathway of heme groups is involved in the regulation of the immune system [142] and that HO-1 plays an important role in the modulation of immune reactions within the tumor [143,144], for instance in the recruitment of immune cells [145]. Within the tumors, HO-1 can be expressed both in cancer cells and/or in infiltrating leucocytes [6].

In colorectal cancer cells (CRC), HO-1 expression directly regulates antitumor immunity reducing the expression of ICAM-1 and CXCL10, which in turn inhibits the adhesion and recruitment of T effector (T$_{\text{eff}}$) cells, inhibiting cell-mediated cytotoxicity [135]. In addition, T$_{\text{reg}}$ recruitment is increased in HO-1-dependent manner in 4T1 breast cancer and in tumor-bearing mice [146] and HO-1 expression in cancer cells is related to the increased generation of IL-10 responsible for keeping DC immaturity [147,148].

The main effector of HO-1 in the regulation of the immune system is its metabolic product CO [142,149] which exerts pleiotropic effects in most immune cell types [149]. For instance, CO blocks DC maturation and modulates their cytokine secretion, inducing a tolerogenic phenotype. It also inhibits proliferation and activation of T$_{\text{eff}}$, induces T$_{\text{reg}}$ expansion [150] and is involved in the early expansion, differentiation, and maturation of myeloid cells into macrophages [142]. Moreover, it has recently been shown that bilirubin can act as endogenous regulator of inflammation, impairing the expression of adhesion molecules [151] and even though the role of HO-1-dependent bilirubin generation in cancer microenvironment has not been demonstrated yet, it seems conceivable that it could play a role in immune-escape.

As far as HO-1 expression in immune cells is concerned, HO-1 is differentially expressed between CD4$^+$CD25$^+$ (T$_{\text{reg}}$) and CD4$^+$CD25$^-$ (T$_{\text{eff}}$) cell populations [141,143]. In human T$_{\text{reg}}$, HO-1 expression directly correlates with the expression of T$_{\text{reg}}$-specific marker FoxP3 [152] and HO-1-derived CO seems to be the mediator of the antiproliferative effects on CD4$^+$T cells through the block of IL-2 production [153]. Moreover, HO-1 overexpression renders T$_{\text{reg}}$ resistant to Fas-mediated apoptosis [154]. Several studies have also demonstrated that T$_{\text{reg}}$ play a pathological role in brain tumor progression [155–157]. In fact, T$_{\text{reg}}$s progressively infiltrate human malignant gliomas and the overexpression of HO-1 is associated with the increased tumor grade and immune suppression [158]. Accordingly, HO-1 expression favors T$_{\text{reg}}$ survival to the hypoxic environment and its inhibition with SnPPIX reduces the number of T$_{\text{reg}}$, resulting in a survival advantage in glioma bearing-mice [148]. In addition, the upregulation of HO-1 in DC favors T$_{\text{reg}}$s recruitment in tumor stromal compartment [159].

However, the presence of T$_{\text{eff}}$ remains useful to cancer recognition. Indeed, recently, Longo and coworkers have demonstrated that a fasting-mimicking diet (FMD) regime in combination with a standard chemotherapy, through the downregulation of HO-1 expression in tumor cells, enhances tumor immunogenicity by stimulating the levels of cytotoxic CD8$^+$ tumor-infiltrating lymphocyte and decreasing the levels of T$_{\text{reg}}$, leading to a major delay in breast and melanoma progression [146].
Moreover, in the tumor microenvironment, the presence of macrophages dramatically influences cancer progression. Indeed, macrophages with a specific polarization phenotype can differentially modulate the growth and the invasiveness of cancer cells, regulating the immune response of T cells as well as angiogenesis and metastatic growth. Depending on their polarization state, macrophages (M1) are able to kill tumor cells and present tumor-associated antigens or exert tumor supportive activities (M2) by promoting invasion and metastasis [160]. HO-1 expression in stromal macrophages in different cancer tissue (e.g., gliomas and melanomas) was observed in the early 2000s [161,162]. HO-1 is involved in macrophage polarization toward a pro-angiogenic, IL-10 producing, M2 phenotype [163–165]. It has been demonstrated that HO-1 positive macrophages induce suppression of the immune response [166] and are associated with poor outcome of cancer patients [160,161,167,168], as shown in breast cancer where HO-1 positive tumor-associated macrophages (TAMs) correlate with an accelerated tumor growth [111]. Moreover, in a transplanted model of pancreatic ductal adenocarcinoma, a subset of M2 macrophages expressing fibroblast activation protein-α (FAP) [169] mediate immune suppression by the induction of HO-1 [166].

Furthermore, a key role in tumor recognition is also played by NK cells which are crucially involved in the early immune-response to tumor cells [170]. In fact, activated NK cells express important receptors (NKp30, NKp44, and NKp46) [171] that recognize specific ligands in tumor [172] inducing apoptosis or recruiting other immune cells [173]. Yet, the interplay between HO-1 and NK-mediated tumor recognition is still poorly understood. It has been shown that the inhibition of HO-1 in different cervical cancer cell lines (CCC), increases the expression of INF-γ and TNF-α in co-cultured NK and restores the expression of NKG2D, NKp30, and NKp46, markers of NK activation [174].

5. Nuclear Localization of HO-1

As previously described, HO-1 protein can localize in multiple subcellular compartments, including mitochondria and caveolae, and also into the nucleus after its c-terminal cleavage. There are several studies showing that HO-1 is preferentially localized into the nucleus in different tumors such as prostate, lung, and oral cancer as well as in chronic myeloid leukemia [13,175–179] and that this localization correlates with cancer progression [13]. In addition, HO-1 nuclear localization has been observed in metastatic cells of prostate cancer [128] and in head and neck cancer [178] as well as in lung A549 and in prostate DU145 cancer cell lines. Moreover, in lung cancer tissue expressing high levels of HO-1, the signal peptide peptidase (SPP) catalyzes the intramembrane cleavage of HO-1 and positive nuclear staining is also evident [177]. In the same paper, it has been shown that the overexpression of a truncated form of HO-1 in cervical carcinoma and in lung cancers promotes cell proliferation and invasion and the tumorigenic effect has also been demonstrated in a mouse model [177]. Interestingly, in chronic myeloid leukemia, HO-1 nuclear translocation is responsible for imatinib resistance. In fact, the treatment with the protease inhibitor Ed64, able to prevent HO-1 nuclear translocation, enhances imatinib-induced cytotoxicity [179].

In support of the hypothesis that nuclear localization of HO-1 could be involved in cancer progression, Biswas and coworkers have shown that nuclear HO-1 interacts with Nrf2, increasing its stabilization. The authors provided evidence of a preferential induction of NQO1 and glucose-6-phosphate dehydrogenase (G6PDH) which favors cell survival by shifting the metabolism to the hexose monophosphate pathway [24,180].

However, it is important to note that there are some opposite observations. In fact, in prostate cancer, nuclear HO-1 localization exerts anti-tumorigenic effects [181] for instance inhibiting cell proliferation, migration, and invasion both in vitro and in vivo [128] or acting on the NF-kB pathway and preventing the angiogenetic switch [129]. Recently, it has been demonstrated that nuclear HO-1 in PCa prostate cancer through the binding to the promoter region of prostate-specific antigen (PSA) acts as a repressor of its transcriptional activity [181].
Nevertheless, the mechanism underlying HO-1 nuclear translocation and its pathological significance among the different tumors needs to be investigated further.

6. HO-1 as a Possible Biomarker

Recently, some studies have been carried out to explore the prognostic significance of HO-1 overexpression in human cancers as well as the possible correlation with tumor clinical features and outcome [84,182,183].

NSCLC patients with metastasis and advanced stage disease (III-IV) exhibit a higher and significant expression of HO-1 as compared to early stage and non-metastatic patients and the expression of HO-1 inversely correlates with patient survival [70]. Notably, HO-1 expression together with Nrf2 activation correlate with tumor differentiation, Nevin staging, and metastasis in gallbladder cancer progression and, as far as Nrf2 is concerned, to overall survival [182]. In cholangiocarcinoma, high HO-1 expression in tumor tissue is associated with poor prognosis and lower survival evaluated using the Kaplan–Meier method [184].

Both HO-1 and Nrf2 expression are elevated in specimens of bladder cancer [185] and, in particular, in tissue specimens from patients with primary non-muscle-invasive bladder cancer (NMIBC) [186] the high expression of HO-1 was detected in 33% of all primary NMIBC cases examined and the expression was significantly associated with adverse pathological characteristics, tumor progression, lower recurrence-free survival, and progression-free survival [186]. Therefore, these findings suggest that high HO-1 expression may be associated with an increased risk of tumor recurrence and disease progression in primary NMIBC, thus indicating a more aggressive phenotype.

Moreover, in neuroblastoma samples, the univariate Kaplan–Meier analysis revealed that high HO-1 RNA expression levels are associated with an unfavorable prognosis [147] and, in histological samples of human glioma, HO-1 expression was higher in comparison to non-malignant brain tissue [187] with no differences among the various tumor grades. However, HO-1 protein expression was associated with a worse prognosis of grade II and III astrocytoma patients [187].

Furthermore, the relationship between high HO-1 expression and chronic myeloid leukemia (CML) progression and relapse has been analyzed. HO-1 mRNA level in CML patients was significantly higher in comparison to donor samples, and its expression significantly increased in relapsing disease, indicating that HO-1 may be a potential molecular indicator for the progression of disease [188].

7. Perspectives and Innovations

In this review, we highlighted the role of HO-1 in favoring tumor progression and eventually its possible use as a biomarker. However, the existence of contrasting data has also been analyzed as it could limit the value of our hypothesis. In this context, we believe it is worth underlining that the effect of HO-1 overexpression is carried out by its metabolic products. Their actions, indeed, can be actually different in the different tissues due to the activity of the other enzymes involved in the degradation pathway of heme. In fact, biliverdin reductase undergoes a tissue- and differentiation-dependent distribution [189,190], influencing the generation of bilirubin. Furthermore, the ability to quench free iron generated from HO-1 can play a role in cancer progression as highlighted by Alkhateeb and Connor [191] who deeply analyzed the role of ferritin expression in cancer cell resistance and in inducing a favorable microenvironment. It is conceivable that the fine balance among all the products derived from heme degradation pathway can lead to pro- or anti-tumorigenic effects.

Finally, it is also important to consider the role of HO-1 in microRNA biogenesis and regulation which are highly tissue- and cell-specific [10] and differently involved in tumor biology. It is clear that the specific role of HO-1 in tumor progression is far from being completely understood but it is clear as well that HO-1, and perhaps all the heme degradation pathways, can be strategically modulated in cancer therapy.

So far, different HO-1 inhibitors have been identified [192]. The metalloporphyrins (e.g., Sn-, Zn-, and Cr-protoporphyrin), structurally similar to heme, have been used as prototypic inhibitors
of HO-1, even though their application is limited by several pitfalls [10]. In fact, ZnPPIX acts also on other pathways such as indoleamine-2,3-dioxygenases, cyclin D1, and Wnt/β-catenin and, due to its poor solubility, its application in vivo is limited [110]. Thus, several modifications of ZnPPIX have been made. The pegylated form PEG-ZnPPIX is characterized by increased circulation time, enhanced permeability and retention [193]. Also, the styrene maleic acid modification SMA-ZnPPIX shows increased effectiveness in term of solubility and uptake [194]. Recently, other water-soluble imidazole-based molecules have been proven to be HO-1 inhibitors with a better specificity towards HO-1 than protoporphyrin compounds, increasing the chances of developing new molecules [192]. In addition, other therapeutic opportunities can derived from the studies of specific siRNA to silence HO-1 or from new tools able to modulated microRNAs involved in HO-1 activity. Finally, the modulation of biliverdin reductase activity [189] or the downregulation of ferritin levels [191] have been proposed as strategies in cancer therapy as well.

8. Conclusions

The upregulation of HO-1 plays a pivotal role in cell adaptation to oxidative/electrophilic stress and to cytotoxic insults. Even though the activation of this powerful system in healthy cells is essential in the prevention of carcinogenesis [69], its activation becomes deleterious in cancer progression. Indeed, a sustained activation of HO-1 in cancer favors tumor growth, metastasis and invasiveness potential, resistance to therapy, as well as modulation of microenvironment and immune-escape, leading to a poor outcome (Figure 2).

![Figure 2](image_url)

**Figure 2.** HO-1 induction prevents cell transformation acting through an antioxidant protective mechanism in healthy cells. However, malignant cells can take advantage of HO-1 upregulation favoring tumor growth, invasion, and metastasis.

The multifaceted role of HO-1 in cancer is mediated mainly by the action of its metabolic products that exert antioxidant, antiapoptotic, and immunomodulatory effects. However, HO-1 could also play a role independently on its enzymatic activity acting as a transcriptional regulator at the nuclear level (Figure 3). In conclusion, the in-depth investigation of these multiple pathways involving HO-1 in cancer biology may improve the therapeutic and the translational potential of HO-1 modulation.
Figure 3. Schematic representation of HO-1 metabolism. HO-1 substrate, co-factors and metabolic products are indicated together with their recognized or hypothesized effects.

Acknowledgments: Grants from MIUR-PRIN 20125S38FA (Mariapaola Nitti) and Genoa University.

Author Contributions: Mariapaola Nitti and Anna Lisa Furfaro conceived and wrote the manuscript; Sabrina Piras, Umberto M. Marinari, Lorenzo Moretta, Maria A. Pronzato and Anna Lisa Furfaro revised literature; Mariapaola Nitti, Lorenzo Moretta and Maria A. Pronzato provided financial support.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Maines, M.D. Heme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 1988, 2, 2557–2568. [PubMed]
2. Gozzelino, R.; Jeney, V.; Soares, M.P. Mechanisms of cell protection by heme oxygenase-1. Annu. Rev. Pharmacol. Toxicol. 2010, 50, 323–354. [CrossRef] [PubMed]
3. Keyse, S.M.; Tyrrell, R.M. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc. Natl. Acad. Sci. USA 1989, 86, 99–103. [CrossRef] [PubMed]
4. Alam, J.; Shibahara, S.; Smith, A. Transcriptional activation of the heme oxygenase gene by heme and cadmium in mouse hepatoma cells. J. Biol. Chem. 1989, 264, 6371–6375. [PubMed]
5. Foresti, R.; Clark, J.E.; Green, C.J.; Motterlini, R. Thiol compounds interact with nitric oxide in regulating heme oxygenase-1 induction in endothelial cells. Involvement of superoxide and peroxynitrite anions. J. Biol. Chem. 1997, 272, 18411–18417. [CrossRef] [PubMed]
6. Grochot-Przeczek, A.; Dulak, J.; Jozkowicz, A. Haem oxygenase-1: Non-canonical roles in physiology and pathology. Clin. Sci. Lond. 2012, 122, 93–103. [CrossRef] [PubMed]
7. Kim, H.P.; Wang, X.; Galbiati, F.; Ryter, S.W.; Choi, A.M. Caveolae compartmentalization of heme oxygenase-1 in endothelial cells. FASEB J. 2004, 18, 1080–1089. [CrossRef] [PubMed]
8. Converso, D.P.; Taille, C.; Carreras, M.C.; Jaitovich, A.; Poderoso, J.J.; Boczkowski, J. HO-1 is located in liver mitochondria and modulates mitochondrial heme content and metabolism. FASEB J. 2006, 20, 1236–1238. [CrossRef] [PubMed]
9. Lin, Q.; Weis, S.; Yang, G.; Weng, Y.H.; Helston, R.; Rish, K.; Smith, A.; Bordner, J.; Polte, T.; Gaunitz, F.; et al. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J. Biol. Chem. 2007, 282, 20621–20633. [CrossRef] [PubMed]
10. Loboda, A.; Jozkowicz, A.; Dulak, J. HO-1/CO system in tumor growth, angiogenesis and metabolism—Targeting HO-1 as an anti-tumor therapy. Vasc. Pharmacol. 2015, 74, 11–22. [CrossRef] [PubMed]
11. Balla, G.; Jacob, H.S.; Balla, J.; Rosenberg, M.; Nath, K.; Apple, F.; Eaton, J.W.; Vercellotti, G.M. Ferritin: A cytoprotective antioxidant strategem of endothelium. *J. Biol. Chem.* 1992, 267, 18148–18153. [PubMed]

12. Baker, H.M.; Anderson, B.F.; Baker, E.N. Dealing with iron: Common structural principles in proteins that transport iron and heme. *Proc. Natl. Acad. Sci. USA* 2003, 100, 3579–3583. [CrossRef] [PubMed]

13. Dennery, P.A. Signaling function of heme oxygenase proteins. *Antioxid. Redox Signal.* 2014, 20, 1743–1753. [CrossRef] [PubMed]

14. Loboda, A.; Jazwa, A.; Grochot-Przeczek, A.; Rutkowski, A.; Cisowski, J.; Agarwal, A.; Jozkowicz, A.; Dulak, J. Heme oxygenase-1 and the vascular bed: From molecular mechanisms to therapeutic opportunities. *Antioxid. Redox Signal.* 2008, 10, 1767–1812. [CrossRef] [PubMed]

15. Dulak, J.; Jozkowicz, A.; Foresti, R.; Kasza, A.; Frick, M.; Huk, I.; Green, C.J.; Pachinger, O.; Weidinger, F.; Motterlini, R. Heme oxygenase activity modulates vascular endothelial growth factor synthesis in vascular smooth muscle cells. *Antioxid. Redox Signal.* 2002, 4, 229–240. [CrossRef] [PubMed]

16. Jozkowicz, A.; Huk, I.; Nigisch, A.; Weigel, G.; Dietrich, W.; Motterlini, R.; Dulak, J. Heme oxygenase and angiogenic activity of endothelial cells: Stimulation by carbon monoxide and inhibition by tin protoporphyrin-ix. *Antioxid. Redox Signal.* 2003, 5, 155–162. [CrossRef] [PubMed]

17. Grochot-Przeczek, A.; Lach, R.; Mis, J.; Skrzypek, K.; Gozdecka, M.; Sroczynska, P.; Dubiel, M.; Rutkowski, A.; Kozakowska, M.; Zagorska, A.; et al. Heme oxygenase-1 accelerates cutaneous wound healing in mice. *PLoS ONE* 2009, 4, e5803. [CrossRef] [PubMed]

18. Stocker, R.; Yamamoto, Y.; McDonagh, A.E.; Glazer, A.N.; Ames, B.N. Bilirubin is an antioxidant of possible physiological importance. *Science* 1987, 235, 1043–1046. [CrossRef] [PubMed]

19. Loboda, A.; Damulewicz, M.; Pyza, E.; Jozkowicz, A.; Dulak, J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: An evolutionarily conserved mechanism. *Cell. Mol. Life Sci.* 2016, 73, 3221–3247. [CrossRef] [PubMed]

20. Dudnik, L.B.; Khrapova, N.G. Characterization of bilirubin inhibitory properties in free radical oxidation reactions. *Membr. Cell Biol.* 1998, 12, 233–240. [PubMed]

21. Baranano, D.E.; Rao, M.; Ferris, C.D.; Snyder, S.H. Biliverdin reductase: A major physiologic cytoprotectant. *Proc. Natl. Acad. Sci. USA* 2002, 99, 16093–16098. [CrossRef] [PubMed]

22. He, M.; Nitti, M.; Piras, S.; Furfaro, A.L.; Traverso, N.; Pronzato, M.A.; Mann, G.E. Heme oxygenase-1-derived bilirubin protects endothelial cells against high glucose-induced damage. *Free Radic. Biol. Med.* 2015, 89, 91–98. [CrossRef] [PubMed]

23. Stagg, J.; Galipeau, J. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. *Curr. Mol. Med.* 2013, 13, 856–867. [CrossRef] [PubMed]

24. Biswas, C.; Shah, N.; Muthu, M.; La, P.; Fernando, A.P.; Sengupta, S.; Yang, G.; Denner, P.A. Nuclear heme oxygenase-1 (HO-1) modulates subcellular distribution and activation of Nrf2, impacting metabolic and anti-oxidant defenses. *J. Biol. Chem.* 2014, 289, 26882–26894. [CrossRef] [PubMed]

25. Anderson, C.P.; Tsai, J.; Chan, W.; Park, C.K.; Tian, L.; Lui, R.M.; Forman, H.J.; Reynolds, C.P. Buthionine sulfoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines. *Eur. J. Cancer* 1997, 33, 2016–2019. [CrossRef]

26. Alam, J.; Cook, J.L. How many transcription factors does it take to turn on the heme oxygenase-1 gene? *Am. J. Respir. Cell. Mol. Biol.* 2007, 36, 166–174. [CrossRef] [PubMed]

27. Canning, P.; Sorrell, F.J.; Bullock, A.N. Structural basis of keap1 interactions with Nrf2. *Free Radic. Biol. Med.* 2015, 88, 101–107. [CrossRef] [PubMed]

28. Sykiotis, G.P.; Bohmann, D. Stress-activated cap’n’collar transcription factors in aging and human disease. *Sci. Signal.* 2010, 3, re3. [CrossRef] [PubMed]

29. Moi, P.; Chan, K.; Asunis, I.; Cao, A.; Kan, Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. *Proc. Natl. Acad. Sci. USA* 1994, 91, 9926–9930. [CrossRef] [PubMed]

30. Furfaro, A.L.; Traverso, N.; Domenicotti, C.; Piras, S.; Moretta, L.; Marinari, U.M.; Pronzato, M.A.; Nitti, M. The Nrf2/HO-1 axis in cancer cell growth and chemoresistance. *Oxid. Med. Cell. Longev.* 2016, 2016, 1958174. [CrossRef] [PubMed]
31. Tebay, L.E.; Robertson, H.; Durant, S.T.; Vitale, S.R.; Penning, T.M.; Dinkova-Kostova, A.T.; Hayes, J.D. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. *Free Radic. Biol. Med.* 2015, 88, 108–146. [CrossRef] [PubMed]

32. Kobayashi, A.; Tong, K.I. Oxidative/electrophilic stress sensor keap1 regulates the rapid turnover of transcription factor Nrf2. *Tanjukushitsu Kakusan Koso Protein Nucleic Acid Enzyme* 2006, 51, 1304–1308. [PubMed]

33. Hirotsu, Y.; Katsuoka, F.; Funayama, R.; Nagashima, T.; Nishida, Y.; Nakayama, K.; Engel, J.D.; Yamamoto, M. Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks. *Nucleic Acids Res.* 2012, 40, 10228–10239. [CrossRef] [PubMed]

34. Itoh, K.; Chiba, T.; Takahashi, S.; Ishii, T.; Igarashi, K.; Katoh, Y.; Oyake, T.; Hayashi, N.; Satoh, K.; Hatayama, I.; et al. An Nrf2/small maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. *Biochem. Biophys. Res. Commun.* 1997, 236, 313–322. [CrossRef] [PubMed]

35. Rushmore, T.H.; Pickett, C.B. Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants. *J. Biol. Chem.* 1990, 265, 14648–14653. [PubMed]

36. Murakami, S.; Motohashi, H. Roles of Nrf2 in cell proliferation and differentiation. *Free Radic. Biol. Med.* 2015, 88, 168–178. [CrossRef] [PubMed]

37. Faraonio, R.; Vergara, P.; Di Marzo, D.; Pierantoni, M.G.; Napolitano, M.; Russo, T.; Cimino, F. P53 suppresses the Nrf2-dependent transcription of antioxidant response genes. *J. Biol. Chem.* 2006, 281, 39776–39784. [CrossRef] [PubMed]

38. Ichimura, Y.; Waguri, S.; Sou, Y.S.; Kageyama, S.; Hasegawa, J.; Ishimura, R.; Saito, T.; Yang, Y.; Kouno, T.; Fukutomi, T.; et al. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. *Mol. Cell* 2013, 51, 618–631. [CrossRef] [PubMed]

39. Taguchi, K.; Fujikawa, N.; Komatsu, M.; Ishii, T.; Unno, M.; Akaike, T.; Motohashi, H.; Yamamoto, M. Keap1 degradation by autophagy for the maintenance of redox homeostasis. *Proc. Natl. Acad. Sci. USA* 2012, 109, 13561–13566. [CrossRef] [PubMed]

40. Rada, P.; Rojo, A.I.; Chowdhry, S.; McMahon, M.; Hayes, J.D.; Cuadrado, A. SCF/β-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. *Mol. Cell. Biol.* 2011, 31, 1121–1133. [CrossRef] [PubMed]

41. Mitsuishi, Y.; Motohashi, H.; Yamamoto, M. The Keap1-Nrf2 system in cancers: Stress response and anabolic metabolism. *Front. Oncol.* 2012, 2, 200. [CrossRef] [PubMed]

42. Shibata, T.; Kokubu, A.; Gotoh, M.; Ojima, H.; Ohta, T.; Yamamoto, M.; Hirohashi, S. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. *Gastroenterology* 2008, 135, 1358–1368. [CrossRef] [PubMed]

43. Shibata, T.; Ohta, T.; Tong, K.I.; Kokubu, A.; Odogawa, R.; Tsuta, K.; Asamura, H.; Yamamoto, M.; Hirohashi, S. Cancer related mutations in Nrf2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. *Proc. Natl. Acad. Sci. USA* 2008, 105, 13568–13573. [CrossRef] [PubMed]

44. Shibata, T.; Saito, S.; Kokubu, A.; Suzuki, T.; Yamamoto, M.; Hirohashi, S. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mtor growth signaling pathway. *Cancer Res.* 2010, 70, 9095–9105. [CrossRef] [PubMed]

45. Muscarella, L.A.; Parrella, P.; D’Alessandro, V.; la Torre, A.; Barbano, R.; Fontana, A.; Tancredi, A.; Guarneri, V.; Balsamo, T.; Coco, M.; et al. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. *Epigenetics* 2011, 6, 710–719. [CrossRef] [PubMed]

46. Zhang, P.; Singh, A.; Yegnasubramanian, S.; Esopi, D.; Kombaira, P.; Bodas, M.; Wu, H.; Bova, S.G.; Biswal, S. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemo-resistance and radio-resistance and promotes tumor growth. *Mol. Cancer Ther.* 2010, 9, 336–346. [CrossRef] [PubMed]

47. Martinez, V.D.; Vucic, E.A.; Thu, K.L.; Pikor, L.A.; Lam, S.; Lam, W.L. Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple genetic mechanisms: Association with poor prognosis in head and neck cancer. *Head Neck* 2015, 37, 727–734. [CrossRef] [PubMed]
48. Hanada, N.; Takahata, T.; Zhou, Q.; Ye, X.; Sun, R.; Itoh, J.; Ishiguro, A.; Kijima, H.; Mimura, J.; Itoh, K.; et al. Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer 2012, 12, 66. [CrossRef] [PubMed]

49. Van der Wijst, M.G.; Brown, R.; Rotz, M.G. Nrf2, the master redox switch: The achilles’ heel of ovarian cancer? Biochim. Biophys. Acta 2014, 1846, 494–509. [CrossRef] [PubMed]

50. Jaramillo, M.C.; Zhang, D.D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013, 27, 2179–2191. [CrossRef] [PubMed]

51. Chen, W.; Sun, Z.; Wang, X.J.; Jiang, T.; Huang, Z.; Fang, D.; Zhang, D.D. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol. Cell 2009, 34, 663–673. [CrossRef] [PubMed]

52. Villeneuve, N.F.; Sun, Z.; Chen, W.; Zhang, D.D. Nrf2 and p21 regulate the fine balance between life and death by controlling ros levels. Cell Cycle 2009, 8, 3255–3256. [CrossRef] [PubMed]

53. Shan, Y.; Wei, Z.; Tao, L.; Wang, S.; Zhang, F.; Shen, C.; Wu, H.; Liu, Z.; Zhu, P.; Wang, A.; et al. Prophylaxis of diallyl disulfide on skin carcinogenic model via p21-dependent Nrf2 stabilization. Sci. Rep. 2016, 6, 35676. [CrossRef] [PubMed]

54. Gan, L.; Johnson, D.A.; Johnson, J.A. Keap1-Nrf2 activation in the presence and absence of DJ-1. Eur. J. Neurosci. 2010, 31, 967–977. [CrossRef] [PubMed]

55. Clements, C.M.; McNally, R.S.; Conti, B.J.; Mak, T.W.; Ting, J.P. DJ-1, a cancer- and Parkinson’s disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl. Acad. Sci. USA 2006, 103, 15091–15096. [CrossRef] [PubMed]

56. MacKeigan, J.P.; Clements, C.M.; Ich, J.D.; Pope, R.M.; Hod, Y.; Ting, J.P. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: Identification of RS/DJ-1 and RhoGDialpha. Cancer Res. 2003, 63, 6928–6934. [PubMed]

57. Saidu, N.E.; Noe, G.; Cerles, O.; Cabel, L.; Kavian-Tessler, N.; Chouzenoux, S.; Bahuaud, M.; Chereau, C.; Nicco, C.; Leroy, K.; et al. Dimethyl fumarate controls the Nrf2/DJ-1 axis in cancer cells: Therapeutic applications. Mol. Cancer Ther. 2017, 16, 529–539. [CrossRef] [PubMed]

58. Davudian, S.; Mansoori, B.; Shajari, N.; Mohammadi, A.; Baradaran, B. BACH1, the master regulator gene: A novel candidate target for cancer therapy. Gene 2016, 588, 30–37. [CrossRef] [PubMed]

59. Ogawa, K.; Sun, J.; Taketani, S.; Nakajima, O.; Nishitani, C.; Sassa, S.; Hayashi, N.; Yamamoto, M.; Shibahara, S.; Fujita, H.; et al. Heme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1. EMBO J. 2001, 20, 2835–2843. [CrossRef] [PubMed]

60. Slebos, D.J.; Ryter, S.W.; van der Toorn, M.; Liu, F.; Guo, F.; Baty, C.J.; Karlsson, J.M.; Watkins, S.C.; Kim, H.P.; Wang, X.; et al. Mitochondrial localization and function of heme oxygenase-1 in cigarette smoke-induced cell death. Am. J. Respir. Cell. Mol. Biol. 2007, 36, 409–417. [CrossRef] [PubMed]

61. Taira, J.; Sugishima, M.; Kida, Y.; Oda, E.; Noguchi, M.; Higashimoto, Y. Caveolin-1 is a competitive inhibitor of heme oxygenase-1 (HO-1) with heme: Identification of a minimum sequence in caveolin-1 for binding to HO-1. Biochemistry 2011, 50, 6824–6831. [CrossRef] [PubMed]

62. Weng, P.; Zhang, X.T.; Sheng, Q.; Tian, W.F.; Chen, J.;; Yuan, J.J.; Zhang, J.R.; Pang, Q.F. Caveolin-1 scaffolding domain peptides enhance anti-inflammatory effect of heme oxygenase-1 through interrupting its interact with caveolin-1. Oncotarget 2017. [CrossRef] [PubMed]

63. Guo, Y.; Yu, S.; Zhang, C.; Kong, A.N. Epigenetic regulation of Keap1-Nrf2 signaling. Free Radic. Biol. Med. 2015, 88, 337–349. [CrossRef] [PubMed]

64. Traverso, N.; Ricciarelli, R.; Nitti, M.; Marengo, B.; Furfaro, A.L.; Pronzato, M.A.; Marinari, U.M.; Domenicotti, C. Role of glutathione in cancer progression and chemoresistance. Oxid. Med. Cell. Longev. 2013, 2013, 972913. [CrossRef] [PubMed]

65. Marengo, B.; Nitti, M.; Furfaro, A.L.; Colla, R.; Ciucis, C.D.; Marinari, U.M.; Pronzato, M.A.; Traverso, N.; Domenicotti, C. Redox homeostasis and cellular antioxidant systems: Crucial players in cancer growth and therapy. Oxid. Med. Cell. Longev. 2016, 2016, 6235641. [CrossRef] [PubMed]

66. Chau, L.Y. Heme oxygenase-1: Emerging target of cancer therapy. J. Biomed. Sci. 2015, 22, 22. [CrossRef] [PubMed]

67. Jozkowicz, A.; Was, H.; Dulak, J. Heme oxygenase-1 in tumors: Is it a false friend? Antioxid. Redox Signal. 2007, 9, 2099–2117. [CrossRef] [PubMed]
68. Moon, E.J.; Giaccia, A. Dual roles of Nrf2 in tumor prevention and progression: Possible implications in cancer treatment. *Free Radic. Biol. Med.* 2015, 79, 292–299. [CrossRef] [PubMed]

69. Na, H.K.; Surh, Y.J. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. *Free Radic. Biol. Med.* 2014, 67, 353–365. [CrossRef] [PubMed]

70. Tsai, J.R.; Wang, H.M.; Liu, P.L.; Chen, Y.H.; Yang, M.C.; Chou, S.H.; Cheng, Y.J.; Yin, W.H.; Hwang, J.J.; Chong, I.W. High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients. *Cell. Oncol.* 2012, 35, 461–471. [CrossRef] [PubMed]

71. Goodman, A.I.; Choudhury, M.; da Silva, J.L.; Schwartzman, M.L.; Abrahams, N.G. Overexpression of the heme oxygenase gene in renal cell carcinoma. *Proc. Soc. Exp. Biol. Med.* 1997, 214, 54–61. [CrossRef] [PubMed]

72. Maines, M.D.; Abrahamsson, P.A. Expression of heme oxygenase-1 (HSP32) in human prostate: Normal, hyperplastic, and tumor tissue distribution. *Urology* 1996, 47, 727–733. [CrossRef]

73. Schacter, B.A.; Kurz, P. Alterations in microsomal drug metabolism and heme oxygenase activity in isolated hepatic parenchymal and sinusoidal cells in murphy-sturm lymphosarcoma-bearing rats. *Clin. Investig. Med. Clin. Exp.* 1986, 9, 150–155.

74. Was, H.; Dulak, J.; Jozkowicz, A. Heme oxygenase-1 in tumor biology and therapy. *Curr. Drug Targets* 2010, 11, 1551–1570. [CrossRef] [PubMed]

75. Miyake, M.; Ishii, M.; Kawashima, K.; Kodama, T.; Sugano, K.; Fujimoto, K.; Hirao, Y. Sirna-mediated knockdown of the heme synthesis and degradation pathways: Modulation of treatment effect of 5-aminolevulinic acid-based photodynamic therapy in urothelial cancer cell lines. *Photochem. Photobiol.* 2009, 85, 1020–1027. [CrossRef] [PubMed]

76. Fang, J.; Greish, K.; Qin, H.; Liao, L.; Nakamura, H.; Takeya, M.; Maeda, H. HSP32 (HO-1) inhibitor, copoly(styrene-maleic acid)-zinc protoporphyrin IX, a water-soluble micelle as anticancer agent: In vitro and in vivo anticancer effect. *Eur. J. Pharm. Biopharm.* 2012, 81, 540–547. [CrossRef] [PubMed]

77. Furfaro, A.L.; Macay, J.R.; Marengo, B.; Nitti, M.; Parodi, A.; Fenoglio, D.; Marinari, U.M.; Pronzato, M.A.; Domenicotti, C.; Traverso, N. Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1. *Free Radic. Biol. Med.* 2012, 52, 488–496. [CrossRef] [PubMed]

78. Tan, Q.; Wang, H.; Hu, Y.; Hu, M.; Li, X.; Aodengqimuge, M.; Wei, C.; Song, L. Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy. *Cancer Sci.* 2015, 106, 1023–1032. [CrossRef] [PubMed]

79. Ly, X.; Song, D.M.; Niu, Y.H.; Wang, B.S. Inhibition of heme oxygenase-1 enhances the chemosensitivity of laryngeal squamous cell cancer Hep-2 cells to cisplatin. *Apoptosis* 2016, 21, 489–501. [CrossRef] [PubMed]

80. Jeon, W.K.; Hong, H.Y.; Seo, W.C.; Lim, K.H.; Lee, H.Y.; Kim, W.J.; Song, S.Y.; Kim, B.C. Smad7 sensitizes A549 lung cancer cells to cisplatin-induced apoptosis through heme oxygenase-1 inhibition. *Biochem. Biophys. Res. Commun.* 2012, 420, 288–292. [CrossRef] [PubMed]

81. Yin, Y.; Liu, Q.; Wang, B.; Chen, G.; Xu, L.; Zhou, H. Expression and function of heme oxygenase-1 in human gastric cancer. *Exp. Biol. Med. Maywood* 2012, 237, 362–371. [CrossRef] [PubMed]

82. Liu, Y.S.; Li, H.S.; Qi, D.F.; Zhang, J.; Jiang, X.C.; Shi, K.; Zhang, X.J.; Zhang, X.H. Zinc protoporphyrin IX enhances chemotherapeutic response of hepatoma cells to cisplatin. *Free Radic. Biol. Med.* 2009, 47, 528–537. [CrossRef] [PubMed]

83. Miyake, M.; Fujimoto, K.; Anai, S.; Ohnishi, S.; Nakai, Y.; Inoue, T.; Matsumura, Y.; Tomioka, A.; Ikeda, T.; Okajima, E.; et al. Inhibition of heme oxygenase-1 enhances the cytotoxic effect of gemcitabine in urothelial cancer cells. *Anticancer Res.* 2010, 30, 2145–2152. [PubMed]

84. Miyake, M.; Fujimoto, K.; Anai, S.; Ohnishi, S.; Nakai, Y.; Inoue, T.; Matsumura, Y.; Tomioka, A.; Ikeda, T.; Tanaka, N.; et al. Clinical significance of heme oxygenase-1 expression in non-muscle-invasive bladder cancer. *Urol. Int.* 2010, 85, 355–363. [CrossRef] [PubMed]

85. Kongpetch, S.; Kukongviriyapan, V.; Prawan, A.; Senggunprai, L.; Kukongviriyapan, U.; Buranrat, B. Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. *PLoS ONE* 2012, 7, e34994. [CrossRef] [PubMed]

86. Berberat, P.O.; Dambrauskas, Z.; Gulbinas, A.; Giese, T.; Giese, N.; Kunzli, B.; Autschbach, F.; Meuer, S.; Buchler, M.W.; Friess, H. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. *Clin. Cancer Res.* 2005, 11, 3790–3798. [CrossRef] [PubMed]
87. Barrera, L.N.; Rushworth, S.A.; Bowles, K.M.; MacEwan, D.J. Bortezomib induces heme oxygenase-1 expression in multiple myeloma. *Cell Cycle* 2012, 11, 2248–2252. [CrossRef] [PubMed]

88. Zhou, P.; Kalakonda, N.; Comenzo, R.L. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): Possible mechanisms to explain ATO resistance in vivo. *Br. J. Haematol.* 2005, 128, 636–644. [CrossRef] [PubMed]

89. Liu, Y.; Liang, Y.; Zheng, T.; Yang, G.; Zhang, X.; Sun, Z.; Shi, C.; Zhao, S. Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cells. *J. Neuro-Oncol.* 2011, 104, 449–458. [CrossRef] [PubMed]

90. Furfaro, A.L.; Piras, S.; Passalacqua, M.; Domenicotti, C.; Parodi, A.; Fenoglio, D.; Pronzato, M.A.; Marinari, U.M.; Moretta, L.; Traverso, N.; et al. HO-1 up-regulation: A key point in high-risk neuroblastoma resistance to bortezomib. *Biochim. Biophys. Acta* 2014, 1842, 613–622. [CrossRef] [PubMed]

91. Furfaro, A.L.; Piras, S.; Domenicotti, C.; Fenoglio, D.; De Luigi, A.; Salmona, M.; Moretta, L.; Marinari, U.M.; Pronzato, M.A.; Traverso, N.; et al. Role of Nrf2, HO-1 and gsh in neuroblastoma cell resistance to bortezomib. *PLoS ONE* 2016, 11, e0152465. [CrossRef] [PubMed]

92. Zhang, W.; Qiao, T.; Zha, L. Inhibition of heme oxygenase-1 enhances the radiosensitivity in human nonsmall cell lung cancer A549 cells. *Cancer Biother. Radiopharm.* 2011, 26, 639–645. [CrossRef] [PubMed]

93. Chen, N.; Wu, L.; Yuan, H.; Wang, J. ROS/Autophagy/Nrf2 pathway mediated low-dose radiation induced radio-resistance in human lung adenocarcinoma A549 cell. *Int. J. Biol. Sci.* 2015, 11, 833–844. [CrossRef] [PubMed]

94. Ohgari, Y.; Miyata, Y.; Miyagi, T.; Gotoh, S.; Ohta, T.; Kataoka, T.; Furuyama, K.; Taketani, S. Roles of porphyrin and iron metabolisms in the delta-aminolevulinic acid (ALA)-induced accumulation of protoporphyrin and photodamage of tumor cells. *Photochem. Photobiol.* 2011, 87, 1138–1145. [CrossRef] [PubMed]

95. Nowis, D.; Legat, M.; Grzela, T.; Niderla, J.; Wilczek, E.; Wilczynski, G.M.; Glogowska, E.; Mrowka, P.; Issat, T.; Dulak, J.; et al. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. *Oncogene* 2006, 25, 3365–3374. [CrossRef] [PubMed]

96. Frank, J.; Lornejad-Schafer, M.R.; Schoffl, H.; Flaccus, A.; Lambert, C.; Biesalski, H.K. Inhibition of heme oxygenase-1 increases responsiveness of melanoma cells to ala-based photodynamic therapy. *Int. J. Oncol.* 2007, 31, 1539–1545. [CrossRef] [PubMed]

97. Zhe, N.; Wang, J.; Chen, S.; Lin, X.; Chai, Q.; Zhang, Y.; Zhao, J.; Fang, Q. Heme oxygenase-1 plays a crucial role in chemoresistance in acute myeloid leukemia. *Hematology* 2015, 20, 384–391. [CrossRef] [PubMed]

98. Lin, X.; Fang, Q.; Chen, S.; Zhe, N.; Chai, Q.; Yu, M.; Zhang, Y.; Wang, Z.; Wang, J. Heme oxygenase-1 suppresses the apoptosis of acute myeloid leukemia cells via the JNK/c-JUN signaling pathway. *Leuk. Res.* 2015, 39, 544–552. [CrossRef] [PubMed]

99. Rushworth, S.A.; Bowles, K.M.; MacEwan, D.J. High basal nuclear levels of Nrf2 in acute myeloid leukaemia reduces sensitivity to proteasome inhibitors. *Cancer Res.* 2011, 71, 1999–2009. [CrossRef] [PubMed]

100. Heasman, S.A.; Zaitseva, L.; Bowles, K.M.; Rushworth, S.A.; Macewan, D.J. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. *Oncotarget* 2011, 2, 658–668. [CrossRef] [PubMed]

101. Mayerhofer, M.; Florian, S.; Krauth, M.T.; Aichberger, K.J.; Bilban, M.; Marculescu, R.; Printz, D.; Fritsch, G.; Wagner, O.; Selzer, E.; et al. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. *Cancer Res.* 2004, 64, 3148–3154. [CrossRef] [PubMed]

102. Cao, L.; Wang, J.; Ma, D.; Wang, P.; Zhang, Y.; Fang, Q. Heme oxygenase-1 contributes to imatinib resistance by promoting autophagy in chronic myeloid leukemia through disrupting the mtor signaling pathway. *Biomed. Pharmacother.* 2016, 78, 30–38. [CrossRef] [PubMed]

103. Wu, W.; Ma, D.; Wang, P.; Cao, L.; Lu, T.; Fang, Q.; Zhao, J.; Wang, J. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells. *FEBS J.* 2016, 283, 834–849. [CrossRef] [PubMed]

104. Zou, C.; Cheng, W.; Li, Q.; Han, Z.; Wang, X.; Jin, J.; Zou, J.; Liu, Z.; Zhou, Z.; Zhao, W.; et al. Heme oxygenase-1 retards hepatocellular carcinoma progression through the microrna pathway. *Oncol. Rep.* 2016, 36, 2715–2722. [CrossRef] [PubMed]
Antioxidants 2017, 6, 29

105. Tertil, M.; Golda, S.; Skrzypek, K.; Florczyk, U.; Weglarczyk, K.; Kotlinowski, J.; Maleszewska, M.; Czauderna, S.; Pichon, C.; Kieda, C.; et al. Nrf2-heme oxygenase-1 axis in mucoepidermoid carcinoma of the lung: Antitumoral effects associated with down-regulation of matrix metalloproteinases. *Free Radic. Biol. Med.* 2015, 89, 147–157. [CrossRef] [PubMed]

106. Was, H.; Cichon, T.; Smolarczyk, R.; Rudnicka, D.; Stopa, M.; Chevalier, C.; Leger, J.J.; Lackowska, B.; Grochot, A.; Bojkowska, K.; et al. Overexpression of heme oxygenase-1 in murine melanoma: Increased proliferation and viability of tumor cells, decreased survival of mice. *Am. J. Pathol.* 2006, 169, 2181–2198. [CrossRef] [PubMed]

107. Tsai, C.F.; Yeh, W.L.; Huang, S.M.; Tan, T.W.; Lu, D.Y. Wogonin induces reactive oxygen species production and cell apoptosis in human glioma cancer cells. *Int. J. Mol. Sci.* 2012, 13, 9877–9892. [CrossRef] [PubMed]

108. Tertil, M.; Skrzypek, K.; Florczyk, U.; Weglarczyk, K.; Was, H.; Collet, G.; Guichard, A.; Gil, T.; Kuzdzal, J.; Jozkowicz, A.; et al. Regulation and novel action of thymidine phosphorylase in non-small cell lung cancer: Crosstalk with Nrf2 and HO-1. *PLoS ONE* 2014, 9, e97070. [CrossRef] [PubMed]

109. Bronckaers, A.; Gago, F.; Balzarini, J.; Liekens, S. The dual role of thymidine phosphorylase in cancer proliferation and viability of tumor cells, decreased survival of mice. *Am. J. Pathol.* 2015, 1859–1869. [CrossRef] [PubMed]

110. Lu, D.Y.; Yeh, W.L.; Huang, S.M.; Tang, C.H.; Lin, H.Y.; Chou, S.J. Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells. *Neuro-Oncol.* 2012, 14, 1367–1378. [CrossRef] [PubMed]

111. Deng, R.; Wang, S.M.; Yin, T.; Ye, T.H.; Shen, G.B.; Li, L.; Zhao, J.Y.; Sang, Y.X.; Duan, X.G.; Wei, Y.Q. Inhibition of tumor growth and alteration of associated macrophage cell type by an HO-1 inhibitor in breast carcinoma-bearing mice. *Oncol. Res.* 2013, 20, 473–482. [CrossRef] [PubMed]

112. Huang, S.M.; Lin, C.; Lin, H.Y.; Chiu, C.M.; Fang, C.W.; Liao, K.F.; Chen, D.R.; Yeh, W.L. Brain-derived neurotrophic factor regulates cell motility in human colon cancer. *Endocr.-Relat. Cancer* 2015, 22, 455–464. [CrossRef] [PubMed]

113. Dey, S.; Sayers, C.M.; Verginadis, I.I.; Lehman, S.L.; Cheng, Y.; Cerniglia, G.J.; Tuttle, S.W.; Feldman, M.D.; Zhang, P.J.; Fuchs, S.Y.; et al. ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. *J. Clin. Investig.* 2015, 125, 169–183. [CrossRef] [PubMed]

114. Yeung, K.T.; Yang, J. Epithelial-mesenchymal transition in tumor metastasis. *Mol. Oncol.* 2017, 11, 28–39. [CrossRef] [PubMed]

115. Choi, Y.S.; Lim, S.; Kim, H.; Lim, H.; Kim, S.; Yoo, J.; Lee, J.; Kim, J.; Park, J.; Kim, J.; et al. Inhibition of tumor growth and alteration of associated macrophage cell type by an HO-1 inhibitor in breast carcinoma-bearing mice. *Oncol. Res.* 2013, 20, 473–482. [CrossRef] [PubMed]

116. Yeung, K.T.; Yang, J. Epithelial-mesenchymal transition in tumor metastasis. *Mol. Oncol.* 2017, 11, 28–39. [CrossRef] [PubMed]

117. Chen, T.; You, Y.; Jiang, H.; Wang, Z.Z. Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation and tumorigenesis. *J. Cell. Physiol.* 2017. [CrossRef] [PubMed]

118. Chang, Y.J.; Chen, W.Y.; Huang, C.Y.; Liu, H.H.; Wei, P.L. Glucose-regulated protein 78 (GRP78) regulates...
123. Jozkowicz, A.; Huk, I.; Nigisch, A.; Weigel, G.; Weidinger, F.; Dulak, J. Effect of prostaglandin-J2 on VEGF synthesis depends on the induction of heme oxygenase-1. Antioxid. Redox Signal. 2002, 4, 577–585. [CrossRef] [PubMed]

124. Deshane, J.; Chen, S.; Caballero, S.; Grochot-Przeczek, A.; Was, H.; Li Calzi, S.; Lach, R.; Hock, T.D.; Chen, B.; Hill-Kapturczak, N.; et al. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J. Exp. Med. 2007, 204, 605–618. [CrossRef] [PubMed]

125. Sunamura, M.; Duda, D.G.; Ghattas, M.H.; Lozonschi, L.; Motoi, F.; Yamauchi, J.; Matsuno, S.; Shibahara, S.; Abraham, N.G. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 2003, 6, 15–24. [CrossRef] [PubMed]

126. Cheng, C.C.; Guan, S.S.; Yang, H.J.; Chang, C.C.; Luo, T.Y.; Chang, J.; Ho, A.S. Blocking heme oxygenase-1 by zinc protoporphyrin reduces tumor hypoxia-mediated VEGF release and inhibits tumor angiogenesis as a potential therapeutic agent against colorectal cancer. J. Biomed. Sci. 2016, 23, 18. [CrossRef] [PubMed]

127. Shang, F.T.; Hui, L.L.; An, X.S.; Zhang, X.C.; Guo, S.G.; Kui, Z. ZnPPIX inhibits peritoneal metastasis of cancer cells. Mol. Cancer Res. 2009, 7, 1745–1755. [CrossRef] [PubMed]

128. Gueron, G.; De Siervi, A.; Ferrando, M.; Salierno, M.; De Luca, P.; Elguero, B.; Meiss, R.; Navone, N.; Vázquez, E.S. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. J. Cancer Res. 2007, 8, 7, 1745–1755. [CrossRef] [PubMed]

129. Ferrando, M.; Gueron, G.; Elguero, B.; Giudice, J.; Salles, A.; Leskow, F.C.; Jares-Erijman, E.A.; Colombo, L.; Meiss, R.; Navone, N.; et al. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis 2011, 14, 467–479. [PubMed]

130. Gueron, G.; Giudice, J.; Valacco, P.; Paez, A.; Elguero, B.; Toscani, M.; Jaworski, F.; Leskow, F.C.; Cotignola, J.; Marti, M.; et al. Heme-oxygenase-1 implications in cell morphology and the adhesive behavior of prostate cancer cells. Oncotarget 2014, 5, 4087–4102. [CrossRef] [PubMed]

131. Vitek, L.; Gbelcova, H.; Muchova, L.; Vanova, K.; Zelenka, J.; Konickova, R.; Suk, J.; Zadinova, M.; Knejzlik, Z.; Ahmad, S.; et al. Anti-proliferative effects of carbon monoxide on pancreatic cancer. Dig. Liver Dis. 2014, 46, 369–375. [CrossRef] [PubMed]

132. Skrzypek, K.; Tertil, M.; Golda, S.; Ciesla, M.; Weglarczyk, K.; Collet, G.; Guichard, A.; Kozakowska, M.; Boczkowski, J.; Was, H.; et al. Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis. Antioxid. Redox Signal. 2013, 19, 644–660. [CrossRef] [PubMed]

133. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 2011, 331, 1565–1570. [CrossRef] [PubMed]

134. Friedl, P.; Wolf, K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3, 362–374. [CrossRef] [PubMed]

135. Seo, G.S.; Jiang, W.Y.; Chi, J.H.; Jin, H.; Park, W.C.; Sohn, D.H.; Park, P.H.; Lee, S.H. Heme oxygenase-1 promotes tumor progression and metastasis of colorectal carcinoma cells by inhibiting antitumor immunity. Oncotarget 2015, 6, 19792–19806. [CrossRef] [PubMed]

136. Ohara, M.; Yamaguchi, Y.; Matsuura, K.; Murakami, S.; Ahiroko, K.; Okada, M. Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol. Immunother. 2009, 58, 441–447. [CrossRef] [PubMed]

137. Junttila, M.R.; de Sauvage, F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501, 346–354. [CrossRef] [PubMed]

138. Beyer, M.; Schultze, J.L. Regulatory T cells in cancer. Blood 2006, 108, 804–811. [CrossRef] [PubMed]

139. Chattopadhyay, S.; Chakraborty, N.G.; Mukherji, B. Regulatory T cells and tumor immunity. Cancer Immunol. Immunother. 2005, 54, 1153–1161. [CrossRef] [PubMed]

140. Kohno, T.; Yamada, Y.; Akamatsu, N.; Kamihira, S.; Imaizumi, Y.; Tomonaga, M.; Matsuyama, T. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci. 2005, 96, 527–533. [CrossRef] [PubMed]

141. Brusko, T.M.; Wasserfall, C.H.; Agarwal, A.; Kapturczak, M.H.; Atkinson, M.A. An integral role for heme oxygenase-1 and carbon monoxide in maintaining peripheral tolerance by CD4+ CD25+ regulatory T cells. J. Immunol. 2005, 174, 5181–5186. [CrossRef] [PubMed]
142. Wegiel, B.; Hedblom, A.; Li, M.; Gallo, D.; Csizmadia, E.; Harris, C.; Nemeth, Z.; Zuckerbraun, B.S.; Soares, M.; Persson, J.L.; et al. Heme oxygenase-1 derived carbon monoxide permits maturation of myeloid cells. *Cell Death Dis.* 2014, 5, e1139. [CrossRef] [PubMed]

143. Pae, H.O.; Oh, G.S.; Choi, B.M.; Chae, S.C.; Chung, H.T. Differential expressions of heme oxygenase-1 gene in CD25− and CD25+ subsets of human CD4+ T cells. *Biochem. Biophys. Res. Commun.* 2003, 306, 701–705. [CrossRef]

144. Chauveau, C.; Remy, S.; Royer, P.J.; Hill, M.; Tanguy-Royer, S.; Hubert, F.X.; Tesson, L.; Brion, R.; Beriou, G.; Gregoire, M.; et al. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. *Blood* 2005, 106, 1694–1702. [CrossRef] [PubMed]

145. Di Biase, S.; Longo, V.D. Fasting-induced differential stress sensitization in cancer treatment. *Mol. Cell. Oncol.* 2016, 3, e117701. [CrossRef] [PubMed]

146. Di Biase, S.; Lee, C.; Brandhorst, S.; Manes, B.; Buono, R.; Cheng, C.W.; Cacciottolo, M.; Martin-Montalvo, A.; de Cabo, R.; Wei, M.; et al. Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity. *Cancer Cell* 2016, 30, 136–146. [CrossRef] [PubMed]

147. Fest, S.; Soldati, R.; Christiansen, N.M.; Zenclussen, M.L.; Kilz, J.; Berger, E.; Starke, S.; Lode, H.N.; Engel, C.; Zenclussen, A.C.; et al. Targeting of heme oxygenase-1 as a novel immune regulator of neuroblastoma. *Int. J. Cancer* 2016, 138, 2030–2042. [CrossRef] [PubMed]

148. Dey, M.; Chang, A.L.; Wainwright, D.A.; Ahmed, A.U.; Han, Y.; Balyasnikova, I.V.; Lesniak, M.S. Heme oxygenase-1 protects regulatory T cells from hypoxia-induced cellular stress in an experimental mouse brain tumor model. *J. Neuroimmunol.* 2014, 266, 33–42. [CrossRef] [PubMed]

149. Wegiel, B.; Hanto, D.W.; Otterbein, L.E. The social network of carbon monoxide in medicine. *Trends Mol. Med.* 2013, 19, 3–11. [CrossRef] [PubMed]

150. Wegiel, B.; Gallo, D.; Csizmadia, E.; Harris, C.; Belcher, J.; Vercellotti, G.M.; Penacho, N.; Seth, P.; Sukhatme, V.; Ahmed, A.; et al. Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. *Cancer Res.* 2013, 73, 7009–7021. [CrossRef] [PubMed]

151. Vogel, M.E.; Zucker, S.D. Bilirubin acts as an endogenous regulator of inflammation by disrupting adhesion molecule-mediated leukocyte migration. *Inflamm. Cell Signal.* 2016, 3, e1178. [PubMed]

152. El Andaloussi, A.; Lesniak, M.S. CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. *J. Neuro-Oncol.* 2007, 83, 145–152. [CrossRef] [PubMed]

153. Pae, H.O.; Oh, G.S.; Choi, B.M.; Chae, S.C.; Kim, Y.M.; Chung, K.R.; Chung, H.T. Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. *J. Immunol.* 2004, 172, 4744–4751. [CrossRef] [PubMed]

154. Choi, B.M.; Pae, H.O.; Jeong, Y.R.; Oh, G.S.; Jun, C.D.; Kim, B.R.; Kim, Y.M.; Chung, H.T. Overexpression of heme oxygenase (HO)-1 renders jurkat T cells resistant to fas-mediated apoptosis: Involvement of iron released by HO-1. *Free Radic. Biol. Med.* 2004, 36, 858–871. [CrossRef] [PubMed]

155. El Andaloussi, A.; Lesniak, M.S. An increase in CD4+ CD25+ FoxP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. *Neuro-Oncol.* 2006, 8, 234–243. [CrossRef] [PubMed]

156. Fecci, P.E.; Mitchell, D.A.; Whitesides, J.F.; Xie, W.; Friedman, A.H.; Archer, G.E.; Herndon, J.E., 2nd; Bignier, D.D.; Dranoff, G.; Sampson, J.H. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. *Cancer Res.* 2006, 66, 3294–3302. [CrossRef] [PubMed]

157. Wainwright, D.A.; Dey, M.; Chang, A.; Lesniak, M.S. Targeting Tregs in malignant brain cancer: Overcoming IDO. *Front. Immunol.* 2013, 4, 116. [CrossRef] [PubMed]

158. Choi, B.M.; Pae, H.O.; Jeong, Y.R.; Kim, Y.M.; Chung, H.T. Critical role of heme oxygenase-1 in FoxP3-mediated immune suppression. *Biochem. Biophys. Res. Commun.* 2005, 327, 1066–1071. [CrossRef] [PubMed]

159. Blancou, P.; Anegon, I. Editorial: Heme oxygenase-1 and dendritic cells: What else? *J. Leuk. Biol.* 2010, 87, 185–187. [CrossRef] [PubMed]

160. Siveen, K.S.; Kuttan, G. Role of macrophages in tumour progression. *Immunol. Lett.* 2009, 123, 97–102. [CrossRef] [PubMed]

161. Nishie, A.; Ono, M.; Shono, T.; Fukushima, J.; Otsubo, M.; Onoue, H.; Ito, Y.; Inamura, T.; Ikezaki, K.; Fukui, M.; et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. *Clin. Cancer Res.* 1999, 5, 1107–1113. [PubMed]
162. Torisu-Itakura, H.; Furue, M.; Kuwano, M.; Ono, M. Co-expression of thymidine phosphorylase and heme oxygenase-1 in macrophages in human malignant vertical growth melanomas. *Jpn. J. Cancer Res.* 2000, 91, 906–910. [CrossRef] [PubMed]

163. Weiõ, N.; Weigert, A.; von Knethen, A.; Brune, B. Heme oxygenase-1 contributes to an alternative macrophage activation profile induced by apotptotic cell supernatants. *Mol. Biol. Cell* 2009, 20, 1280–1288. [CrossRef] [PubMed]

164. Hao, N.B.; Lu, M.H.; Fan, Y.H.; Cao, Y.L.; Zhang, Z.R.; Yang, S.M. Macrophages in tumor microenvironments and the progression of tumors. *Clin. Dev. Immunol.* 2012, 2012, 948098. [CrossRef] [PubMed]

165. Martinez, F.O.; Sica, A.; Mantovani, A.; Locati, M. Macrophage activation and polarization. *Front. Biosci.* 2008, 13, 453–461. [CrossRef] [PubMed]

166. Arnold, J.N.; Magiera, L.; Kraman, M.; Fearon, D.T. Tumoral immune suppression by macrophages expressing fibroblast activation protein-alpha and heme oxygenase-1. *Cancer Immunol. Res.* 2014, 2, 121–126. [CrossRef] [PubMed]

167. Pietra, G.; Manzini, C.; Rivara, S.; Vitale, M.; Cantoni, C.; Petretto, A.; Balsamo, M.; Conte, R.; Benelli, R.; Pietrini, S.; et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. *Cancer Res.* 2006, 66, 605–612. [CrossRef] [PubMed]

168. Kraman, M.; Bambrough, P.J.; Arnold, J.N.; Roberts, E.W.; Magiera, L.; Jones, J.O.; Gopinathan, A.; Tuveson, D.A.; Fearon, D.T. Suppression of antitumor immunity by stromal cells expressing heme oxygenase-1. *J. Innate Immun.* 2011, 3, 216–226. [CrossRef] [PubMed]

169. Gross, E.; Sunwoo, J.B.; Bui, J.D. Cancer immunosurveillance and immunoediting by natural killer cells. *Cancer J.* 2013, 19, 483–489. [CrossRef] [PubMed]

170. Torisu-Itakura, H.; Furue, M.; Kuwano, M.; Ono, M. Co-expression of thymidine phosphorylase and heme oxygenase-1 in macrophages in human malignant vertical growth melanomas. *Jpn. J. Cancer Res.* 2000, 91, 906–910. [CrossRef] [PubMed]

171. Hsu, F.F.; Yeh, C.T.; Sun, Y.J.; Chiang, M.T.; Lan, W.M.; Li, F.A.; Lee, W.H.; Chau, L.Y. Signal peptide peptidase-mediated nuclear localization of heme oxygenase-1 promotes cancer cell proliferation and invasion independent of its enzymatic activity. *Oncogene* 2015, 34, 2410–2411. [CrossRef] [PubMed]

172. Degese, M.S.; Mendizabal, J.E.; Gandini, N.A.; Gutkind, J.S.; Molinolo, A.; Hewitt, S.M.; Curtino, A.C.; Coso, O.A.; Facchinetti, M.M. Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data. *Lung Cancer* 2012, 77, 168–175. [CrossRef] [PubMed]

173. Hsu, F.F.; Yeh, C.T.; Sun, Y.J.; Chiang, M.T.; Lan, W.M.; Li, F.A.; Lee, W.H.; Chau, L.Y. Signal peptide peptidase-mediated nuclear localization of heme oxygenase-1 promotes cancer cell proliferation and invasion independent of its enzymatic activity. *Oncogene* 2015, 34, 2410–2411. [CrossRef] [PubMed]

174. Gomez-Lomeli, P.; Bravo-Cuellar, A.; Hernandez-Flores, G.; Jave-Suarez, L.F.; Aguilar-Lemarroy, A.; Mohamed, E. Nuclear translocation of heme oxygenase-1 is associated to prostate cancer. *Jpn. J. Cancer Res.* 2008, 99, 1043–1056. [CrossRef] [PubMed]

175. Facchinetti, M.M.; Curino, A.C. Nuclear localization of heme oxygenase-1 is associated with tumor progression of head and neck squamous cell carcinomas. *Exp. Mol. Pathol.* 2012, 92, 237–245. [CrossRef] [PubMed]

176. Beckner, M.E.; Stracke, M.L.; Liotta, L.A.; Schiffmann, E. Glycolysis as primary energy source in tumor cell chemotaxis. *J. Natl. Cancer Inst.* 1990, 82, 1836–1840. [CrossRef] [PubMed]

177. Elguero, B.; Gueron, G.; Giudice, J.; Toscani, M.A.; De Luca, F.; Zalazar, F.; Coluccio-Leskow, F.; Meiss, R.; Navone, N.; De Siervi, A.; et al. Unveiling the association of STAT3 and HO-1 in prostate cancer: Role beyond heme degradation. *Neoplasia* 2012, 14, 1043–1056. [CrossRef] [PubMed]
182. Wang, J.; Zhang, M.; Zhang, L.; Cai, H.; Zhou, S.; Zhang, J.; Wang, Y. Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival. *J. Surg. Res.* 2010, 164, e99–e105. [CrossRef] [PubMed]

183. Yokoyama, S.; Mita, S.; Okabe, A.; Abe, M.; Ogawa, M. Prediction of radiosensitivity in human esophageal squamous cell carcinomas with heme oxygenase-1: A clinicopathological and immunohistochemical study. *Oncol. Rep.* 2001, 8, 355–358. [CrossRef] [PubMed]

184. Kongpetch, S.; Puapairoj, A.; Ong, C.K.; Senggunprai, L.; Prawan, A.; Kukongviriyapan, U.; Chan-On, W.; Siew, E.Y.; Khuntikeo, N.; Teh, B.T.; et al. Haem oxygenase 1 expression is associated with prognosis in cholangiocarcinoma patients and with drug sensitivity in xenografted mice. *Cell Prolif.* 2016, 49, 90–101. [CrossRef] [PubMed]

185. Kozakowska, M.; Dobrowolska-Glazar, B.; Okon, K.; Jozkowicz, A.; Dobrowolski, Z.; Dulak, J. Preliminary analysis of the expression of selected proangiogenic and antioxidant genes and micrnas in patients with non-muscle-invasive bladder cancer. *J. Clin. Med.* 2016, 5, 29. [CrossRef] [PubMed]

186. Kim, J.H.; Park, J. Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer. *Hum. Pathol.* 2014, 45, 1830–1838. [CrossRef] [PubMed]

187. Gandini, N.A.; Fermento, M.E.; Salomon, D.G.; Obiol, D.J.; Andres, N.C.; Zenklusen, J.C.; Arevalo, J.; Blasco, J.; Lopez Romero, A.; Facchinetti, M.M.; et al. Heme oxygenase-1 expression in human gliomas and its correlation with poor prognosis in patients with astrocytoma. *Tumour Biol.* 2014, 35, 2803–2815. [CrossRef] [PubMed]

188. Wei, S.; Wang, Y.; Chai, Q.; Fang, Q.; Zhang, Y.; Lu, Y.; Wang, J. Over-expression of heme oxygenase-1 in peripheral blood predicts the progression and relapse risk of chronic myeloid leukemia. *Chin. Med. J.* 2014, 127, 2795–2801. [PubMed]

189. Gibbs, P.E.; Miralem, T.; Maines, M.D. Biliverdin reductase: A target for cancer therapy? *Front. Pharmacol.* 2015, 6, 119. [CrossRef] [PubMed]

190. O’Brien, L.; Hosick, P.A.; John, K.; Stec, D.E.; Hinds, T.D., Jr. Biliverdin reductase isozymes in metabolism. *Trends Endocrinol. Metab.* 2015, 26, 212–220.

191. Alkhateeb, A.A.; Connor, J.R. The significance of ferritin in cancer: Anti-oxidation, inflammation and tumorigenesis. *Biochim. Biophys. Acta* 2013, 1836, 245–254. [CrossRef] [PubMed]

192. Pittala, V.; Salerno, L.; Romeo, G.; Modica, M.N.; Siracusa, M.A. A focus on heme oxygenase-1 (HO-1) inhibitors. *Curr. Med. Chem.* 2013, 20, 3711–3732. [CrossRef] [PubMed]

193. Sahoo, S.K.; Sawa, T.; Fang, J.; Tanaka, S.; Miyamoto, Y.; Akaike, T.; Maeda, H. Pegylated zinc protoporphyrin: A water-soluble heme oxygenase inhibitor with tumor-targeting capacity. *Bioconjug. Chem.* 2002, 13, 1031–1038. [CrossRef] [PubMed]

194. Iyer, A.K.; Greish, K.; Seki, T.; Okazaki, S.; Fang, J.; Takeshita, K.; Maeda, H. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. *J. Drug Target.* 2007, 15, 496–506. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).